The incidence of Type 1 Diabetes Mellitus (T1DM) is rising rapidly, at a rate of approximately 2–5% per year worldwide. Patients are being diagnosed at younger ages, and are living longer due to improved treatment options; resulting in an increase in the size of the treatment population. Furthermore, there is a strong trend in the pipeline for the development of non-insulin therapies. These include adjuvant therapies capable of reducing hyperglycemia in an insulin-independent manner, as well as products capable of disrupting the pathological immune-mediated destruction of pancreatic beta cells, which occurs in most forms of T1DM. Will the emergence of these therapies drive the market growth over the forecast period? Will the latter category have a greater impact on the treatment algorithm over the longer term?
Find out more in GBI Research’s Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 – Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations report. This includes an analysis of the leading insulin therapies in the current T1DM marketed products landscape, a breakdown of pipeline molecules by stage of development, molecule type, route of administration, molecular target and novelty and a comparative analysis of the most promising pipeline molecules is also provided.
Single User Price: $4,995 – Pages: 147